When stomach (gastric) cancer spreads to the peritoneum (the thin membrane lining the abdomen), the path forward often looks a little different from earlier stages. Tiny cancer cells scattered across the peritoneum frequently do not show up clearly on imaging, so doctors usually gather several pieces of information together before settling on a treatment plan. For this reason, gastric cancer with suspected or confirmed peritoneal spread is sometimes treated not only with intravenous (systemic) chemotherapy, but also with medicine delivered straight into the abdominal cavity.
Chemotherapy placed directly into the belly is commonly called intraperitoneal chemotherapy (IP). A small drug-delivery device (a chemo port) is often implanted under the skin of the chest or arm, and a thin tube connected to it carries the medicine into the abdominal cavity. The goal is to let the drug reach the surface of the peritoneum at a closer range and higher concentration. In gastric peritoneal disease, taxane-class drugs given into the abdomen, combined with oral or intravenous agents, are an approach under active study. Because parts of this strategy are still being established, it is frequently carried out within clinical trials.
After a period of treatment, the team looks again at what is happening inside the body. Periodic CT scans track changes in the thickness of the peritoneum or in known lesions, and an upper endoscopy checks the original tumor site. A whitish area left on a scan may represent living cancer, or it may be a residual mark of treatment such as scar tissue (fibrosis) — imaging alone cannot always tell. So clinicians interpret the overall trend across several tests rather than from one picture.
One key step in judging whether surgery is feasible is a staging laparoscopy. Through small incisions, a camera is placed inside to inspect the peritoneum directly. Suspicious areas may be sampled for a rapid frozen-section examination, and fluid washed from the abdominal cavity may be collected for peritoneal cytology to look for cancer cells. If the cancer in the peritoneum has shrunk enough or is no longer seen, the team may discuss a next step such as removing part of the stomach. If cancer cells are still present, the plan may instead be to continue chemotherapy and reassess later.
This process varies from person to person and from one set of results to the next. How long to continue chemotherapy, how much of the stomach to remove if surgery is done, and whether the pylorus (the stomach's outlet) can be preserved are decisions revisited at each stage rather than fixed all at once. The important point is that 'peritoneal spread' is not a simple dead end; treatment response is watched closely so that the next options can be opened up step by step. If you have questions or worries, jotting them down before a visit and asking your oncology and surgical team directly is the best approach.
This article is general health information and does not replace diagnosis or treatment for any individual. Please discuss your own condition and treatment plan with your medical team.